DaVita upgraded to Buy from Neutral at Nomura Nomura expects DaVita to benefit from structural changes in U.S. healthcare, leverage to government's savings initiatives, and share gains in commercial dialysis care patients. Price target is $121.
News For DVA From The Last 14 Days
Check below for free stories on DVA the last two weeks.